Kura Oncology (NASDAQ:KURA) Earns Buy Rating from HC Wainwright

Kura Oncology (NASDAQ:KURA)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright in a report issued on Wednesday,Benzinga reports. They presently have a $32.00 target price on the stock. HC Wainwright’s target price would indicate a potential upside of 80.08% from the stock’s previous close.

Several other equities research analysts also recently commented on the stock. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research note on Tuesday, October 22nd. JMP Securities reiterated a “market outperform” rating and set a $32.00 price objective on shares of Kura Oncology in a research note on Monday, August 12th. Stifel Nicolaus downgraded shares of Kura Oncology from a “buy” rating to a “hold” rating and lowered their price objective for the stock from $26.00 to $19.00 in a research note on Monday, October 14th. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, August 22nd. Finally, UBS Group started coverage on shares of Kura Oncology in a research report on Thursday, October 24th. They set a “buy” rating and a $27.00 target price for the company. One research analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $28.83.

Kura Oncology Price Performance

NASDAQ KURA opened at $17.77 on Wednesday. The firm’s fifty day simple moving average is $18.85 and its two-hundred day simple moving average is $19.99. The company has a current ratio of 14.94, a quick ratio of 14.94 and a debt-to-equity ratio of 0.02. Kura Oncology has a 12-month low of $8.17 and a 12-month high of $24.17. The firm has a market capitalization of $1.36 billion, a P/E ratio of -7.97 and a beta of 0.86.

Kura Oncology (NASDAQ:KURA) last released its quarterly earnings results on Thursday, August 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.63) by $0.04. During the same quarter in the previous year, the business earned ($0.53) earnings per share. Kura Oncology’s revenue was up .0% on a year-over-year basis. Analysts forecast that Kura Oncology will post -2.46 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. nVerses Capital LLC acquired a new position in shares of Kura Oncology in the third quarter worth about $25,000. SG Americas Securities LLC acquired a new position in shares of Kura Oncology in the first quarter worth about $110,000. Quarry LP acquired a new position in shares of Kura Oncology in the second quarter worth about $196,000. Entropy Technologies LP acquired a new position in shares of Kura Oncology in the first quarter worth about $218,000. Finally, China Universal Asset Management Co. Ltd. raised its position in shares of Kura Oncology by 64.7% in the third quarter. China Universal Asset Management Co. Ltd. now owns 14,739 shares of the company’s stock worth $288,000 after acquiring an additional 5,788 shares during the period.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.